Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice

Pharmazie

Volumn 68, Issue 1, 2013, Pages 58-62

  Son, Jin Pub ^a   Son, Mi Kyung ^b   Jun, Seoung Wook ^b   Kwak, Hyun Hee ^b   Kang, Soo Hyoung ^b   Kang, Jung Seok ^b   Park, Young In ^a  

^a Korea University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DA 3091; ENDOTOXIN; EXENDIN 4; GLUCOSE; MICROSPHERE; SIBUTRAMINE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CHOLESTEROL; PEPTIDE; PRODRUG; SUCROSE; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; LIPID DIET; LIPID LIVER LEVEL; LIVER INJURY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; SUSTAINED RELEASE FORMULATION; WEIGHT GAIN; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; DELAYED RELEASE FORMULATION; DRUG EFFECT; FAT INTAKE; FATTY LIVER; GLUCOSE BLOOD LEVEL; LIVER; LIVER DISEASE; LIVER FUNCTION TEST; MALE; METABOLISM; ORGAN SIZE; PATHOLOGY;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DELAYED-ACTION PREPARATIONS; DIETARY FATS; ENDOTOXINS; FATTY LIVER; HYPOGLYCEMIC AGENTS; LIVER; LIVER FUNCTION TESTS; MALE; MICE; MICE, INBRED C57BL; MICROSPHERES; OBESITY; ORGAN SIZE; PEPTIDES; PRODRUGS; SUCROSE; VENOMS;

EID: 84877746132     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.2125     Document Type: Article

References (22)

1. Abdelmalek MF, Diehl AM (2007) Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin Nor Am 91: 1125-1149.
2. Bray GA (2007) Medical consequences of obesity. J Clin Endocrinol Metab 89: 2583-2589.
3. Brun P, Castagliuolo I, Leo VD, Buda A, Pinzani M, Palu G, Martines D (2007) Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 292: G518-525.
4. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628-2635.
5. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C,Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R (2007) Metabolic Endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761-1772.
6. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck M, Delzenne NM, Burcelin R (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57: 1470-1481.
7. Den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA (2004) Hepatic steatosis: a mediator of the metabolic syndrome, lessons from animal models. Arterioscler Thromb Vasc Biol 24: 644-649.
8. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, Heine R (2005) Metabolic syndrome and 10-year cardiovascular disease risk in the hoorn study. Circulation 112: 666-673.
9. Dowman JK, Armstrong JW, Tomlinson, Newsome PN (2011) Current therapeutic strategies in non alcoholic fatty liver disease. Diabetes Obes Metab 13: 692-702.
10. Drucker D (2003). Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26: 2929-2940.
11. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267: 7402-7405.
12. Expert Panel (2001). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 285: 2486-2497.
13. Kim W, Egan JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60: 470-512.
14. Kwak H-H, ShimW-S, Hwang S, Son M-K, Kim Y-Y, Kim T-H, Yoon Z-H, Youn H-J, Lee G-I, Kang S-H, Shim C-K (2009) Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker Diabetic Fatty (ZDF) rats. Pharm Res 26: 2504-2512.
15. Kwak H-H, Shim W-S, Hwang S, Son M-K, Kim Y-Y, Kim T-H, Youn H-J, Kang S-H, Shim C-K (2010) Efficacy of a new sustained-release microsphere formulation of exenatide,DA-3091, in Zucker Diabetic Fatty (ZDF) rats. Eur J Pharm Sci 40: 103-109.
16. Maggio CA, Pi-Sunyer FX (2003) Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 32: 805-822.
17. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors. J Am Med Assoc 289: 76-79.
18. Nielsen LL, Baron AD (2003) Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Invest Drugs 4: 401-405.
19. Nielsen LL, Young AA, Parkes DG (2004) Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Peptides 117: 77-88.
20. NozakiY, Fujita K,Yoneda M,Wada K, ShinoharaY,Takahashi H, Kirikoshi H, Inamori M, Kubota K, Saito S, Mizoue T, Masaki N, Nagashima Y, Terauchi Y, Nakajima A (2009) Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 51: 548-556.
21. Postic C, Cirard J (2008) The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 34: 643-648.
22. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I (2009) Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 50: 1094-1104.